Overview

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Solabegron